|
1
|
Medinger M, Lengerke C and Passweg J:
Novel therapeutic options in acute myeloid leukemia. Leuk Res Rep.
6:39–49. 2016.PubMed/NCBI
|
|
2
|
Southam CM, Craver LF, Dargeon HW and
Burchenal JH: A study of the natural history of acute leukemia with
special reference to the duration of the disease and the occurrence
of remissions. Cancer. 4:39–59. 1951. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Juliusson G, Antunovic P, Derolf A,
Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A and
Höglund M: Age and acute myeloid leukemia: Real world data on
decision to treat and outcomes from the Swedish acute leukemia
registry. Blood. 30:4179–4187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berger DP, Mertelsmann R and Duyster J;
Tumorzentrum Freiburg- CCCF (eds). Das Rote Buch, : Hämatologie und
internistische Onkologie. überarbeitete und erweiterte Auflage.
Landsberg am Lech: ecomed Medizin. p14002017.
|
|
5
|
Patel JP, Gönen M, Figueroa ME, Fernandez
H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S,
Aminova O, et al: Prognostic relevance of integrated genetic
profiling in acute myeloid leukemia. N Engl J Med. 22:1079–1089.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Papaemmanuil E, Gerstung M, Bullinger L,
Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F,
Bolli N, et al: Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 9:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network, ;
Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG,
Hoadley K, Triche TJ Jr, Laird PW, et al: Genomic and epigenomic
landscapes of adult de novo acute myeloid leukemia. N Engl J Med.
30:2059–2074. 2013.PubMed/NCBI
|
|
8
|
Talati C and Sweet K: Recently approved
therapies in acute myeloid leukemia: A complex treatment landscape.
Leuk Res. 73:58–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dugan J and Pollyea D: Enasidenib for the
treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol.
3:755–760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pollyea DA: New drugs for acute myeloid
leukemia inspired by genomics and when to use them. Hematology Am
Soc Hematol Educ Program. 30:45–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Egan PC and Reagan JL: The return of
gemtuzumab ozogamicin: A humanized anti-CD33 monoclonal
antibody-drug conjugate for the treatment of newly diagnosed acute
myeloid leukemia. Onco Targets Ther. 11:8265–8272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCafferty J, Griffiths AD, Winter G and
Chiswell DJ: Phage antibodies: Filamentous phage displaying
antibody variable domains. Nature. 348:552–524. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Breitling F, Dübel S, Seehaus T,
Klewinghaus I and Little M: A surface expression vector for
antibody screening. Gene. 15:147–153. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Frei JC and Lai JR: Protein and antibody
engineering by phage display. Methods Enzymol. 5806:45–87. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barbas III CF, Burton DR, Scott JK and
Silverman GJ: Phage Display: A Laboratory Manual. Cold Spring
Harbor Laboratory; New York, NY: 2004, PubMed/NCBI
|
|
16
|
Smith GP and Petrenko VA: Phage display.
Chem Rev. 97:391–410. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tur MK, Rothe A, Huhn M, Goerres U, Klimka
A, Stöcker M, Engert A, Fischer R, Finner R and Barth S: A novel
approach for immunization, screening and characterization of
selected scFv libraries using membrane fractions of tumor cells.
Int J Mol Med. 11:523–527. 2003.PubMed/NCBI
|
|
18
|
Ten Haaf A, Gattenlöhner S and Tur MK:
Antibody selection on FFPE tissue slides. Methods Mol Biol.
1701:381–391. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fitting J, Blume T, Ten Haaf A, Blau W,
Gattenlöhner S, Tur MK and Barth S: Phage display-based generation
of novel internalizing antibody fragments for immunotoxin-based
treatment of acute myeloid leukemia. MAbs. 7:390–402. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ljungars A, Svensson C, Carlsson A,
Birgersson E, Tornberg UC, Frendéus B, Ohlin M and Mattsson M: Deep
mining of complex antibody phage pools generated by cell panning
enables discovery of rare antibodies binding new targets and
epitopes. Front Pharmacol. 10:8472019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bakker ABH, van den Oudenrijn S, Bakker
AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl
N, Geuijen CA, et al: C-type lectin-like molecule-1: A novel
myeloid cell surface marker associated with acute myeloid leukemia.
Cancer Res. 15:8443–8450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Geuijen CAW, Bijl N, Smit RCM, Cox F,
Throsby M, Visser TJ, Jongeneelen MA, Bakker AB, Kruisbeek AM,
Goudsmit J and de Kruif J: A proteomic approach to tumour target
identification using phage display, affinity purification and mass
spectrometry. Eur J Cancer. 41:178–187. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
ten Haaf A, Pscherer S, Fries K, Barth S,
Gattenlöhner S and Tur MK: Phage display-based on-slide selection
of tumor-specific antibodies on formalin-fixed paraffin-embedded
human tissue biopsies. Immunol Lett. 166:65–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sidney LE, Branch MJ, Dunphy SE, Dua HS
and Hopkinson A: Concise review: Evidence for CD34 as a common
marker for diverse progenitors. Stem Cells. 32:1380–1289. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leach RM, Drummond M, Doig A, McKay P,
Jackson B and Bain BJ: Practical Flow Cytometry in Haematology: 100
worked examples. John Wiley and Sons, Inc.; Hoboken, NJ: 2015,
View Article : Google Scholar
|
|
26
|
Fitting J, Killian D, Junghanss C,
Willenbrock S, Escobar HM, Lange S, Nolte I, Barth S and Tur MK:
Generation of recombinant antibody fragments that target canine
dendritic cells by phage display technology. Vet Comp Oncol.
9:183–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sánchez-Martín D, Sørensen MD, Lykkemark
S, Sanz L, Kristensen P, Ruoslahti E and Álvarez-Vallina L:
Selection strategies for anticancer antibody discovery: Searching
off the beaten path. Trends Biotechnol. 33:292–301. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jäger S, Jahnke A, Wilmes T, Adebahr S,
Vögtle FN, Delima-Hahn E, Pfeifer D, Berg T, Lübbert M and Trepel
M: Leukemia-targeting ligands isolated from phage-display peptide
libraries. Leukemia. 21:411–420. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galili N, Devemy E and Raza A: Isolation
of specific and biologically active peptides that bind cells from
patients with acute myeloid leukemia (AML). J Hematol Oncol.
10:82008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karjalainen K, Jaalouk DE, Bueso-Ramos CE,
Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien
S, Kantarjian HM, et al: Targeting neuropilin-1 in human leukemia
and lymphoma. Blood. 20:920–927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nodehi SM, Repp R, Kellner C, Bräutigam J,
Staudinger M, Schub N, Peipp M, Gramatzki M and Humpe A: Enhanced
ADCC activity of affinity maturated and Fc-engineered
mini-antibodies directed against the AML stem cell antigen CD96.
PLoS One. 7:e424262012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hoen PA, Jirka SM, ten Broeke BR, Schultes
EA, Aguilera B, Pang KH, Heemskerk H, Aartsma-Rus A, van Ommen GJ
and den Dunnen JT: Phage display screening without repetitious
selection rounds. Anal Biochem. 421:622–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luttmann W, Bratke K, Küpper M and Myrtek
D: Der Experimentator: Immunologie. Springer; Heidelberg: 2014,
View Article : Google Scholar
|
|
34
|
Ngai PK, Ackermann F, Wendt H, Savoca R
and Bosshard HR: Protein A antibody-capture ELISA (PACE): An ELISA
format to avoid denaturation of surface-adsorbed antigens. J
Immunol Methods. 158:267–276. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nikfarjam S, Tohidkia MR, Mehdipour T,
Soleimani R, Rahimi AA and Nouri M: Successful application of whole
cell panning for isolation of phage antibody fragments specific to
differentiated gastric cancer cells. Adv Pharm Bull. 9:624–631.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jones ML, Alfaleh MA, Kumble S, Zhang S,
Osborne GW, Yeh M, Arora N, Hou JJ, Howard CB, Chin DY and Mahler
SM: Targeting membrane proteins for antibody discovery using phage
display. Sci Rep. 6:262402016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Derda R, Tang S, Li SC, Ng S, Matochko W
and Jafari MR: Diversity of phage-displayed libraries of peptides
during panning and amplification. Molecules. 21:1776–1803. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Naeim F, Nagesh Rao P, Song SX and Phan
RT: Principles of Immunophenotyping. Atlas of Hematopathology.
Elsevier; pp. 29–56. 2018, View Article : Google Scholar
|
|
39
|
Ricart AD: Antibody-drug conjugates of
calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab
ozogamicin. Clin Cancer Res. 15:6417–6427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vercauteren SM, Zapf R and Sutherland HJ:
Primitive AML progenitors from most CD34(+) patients lack CD33
expression but progenitors from many CD34(−) AML patients express
CD33. Cytotherapy. 9:194–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matsui H, Takeshita A, Naito K, Shinjo K,
Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi
K and Ohno R: Reduced effect of gemtuzumab ozogamicin (CMA-676) on
P-glycoprotein and/or CD34-positive leukemia cells and its
restoration by multidrug resistance modifiers. Leukemia.
16:813–819. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wells SJ, Bray RA, Stempora LL and Farhi
DC: CD117/CD34 expression in leukemic blasts. Am J Clin Pathol.
1:192–195. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alfaleh MA, Jones ML, Howard CB and Mahler
SM: Strategies for selecting membrane protein-specific antibodies
using phage display with cell-based panning. Antibodies (Basel).
5:102017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu Y, McKenna RW, Wilson KS, Karandikar
NJ, Schultz RA and Kroft SH: Immunophenotypic identification of
acute myeloid leukemia with monocytic differentiation. Leukemia.
20:1321–1324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Reader RH, Workman RG, Maddison BC and
Gough KC: Advances in the production and batch reformatting of
phage antibody libraries. Mol Biotechnol. 61:801–815. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pokorny NJ, Boulter-Bitzer JI, Hall JC,
Trevors JT and Lee H: Inhibition of Cryptosporidium parvum
infection of a mammalian cell culture by recombinant scFv
antibodies. Antonie Van Leeuwenhoek. 94:353–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu S, Ke A and Doudna JA: A fast and
efficient procedure to produce scFvs specific for large
macromolecular complexes. J Immunol Methods. 318:95–101. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Boulter-Bitzer JI, Lee H and Trevors JT:
Single-chain variable fragment antibodies selected by phage display
against the sporozoite surface antigen P23 of cryptosporidium
parvum. J Parasitol. 95:75–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Marcus WD, Lindsay SM and Sierks MR:
Identification and repair of positive binding antibodies containing
randomly generated amber codons from synthetic phage display
libraries. Biotechnol Prog. 2:919–922. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang W, Samanta M, Crawford SE, Estes MK,
Neill FH, Atmar RL and Palzkill T: Identification of human
single-chain antibodies with broad reactivity for noroviruses.
Protein Eng Des Sel. 27:339–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vodnik M, Zager U, Strukelj B and Lunder
M: Phage display: Selecting straws instead of a needle from a
haystack. Molecules. 19:790–817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Thomas WD, Golomb M and Smith GP:
Corruption of phage display libraries by target-unrelated clones:
Diagnosis and countermeasures. Anal Biochem. 407:237–240. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kuzmicheva GA, Jayanna PK, Sorokulova IB
and Petrenko VA: Diversity and censoring of landscape phage
libraries. Protein Eng Des Sel. 22:9–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brammer LA, Bolduc B, Kass JL, Felice KM,
Noren CJ and Hall MF: A target-unrelated peptide in an M13 phage
display library traced to an advantageous mutation in the gene II
ribosome-binding site. Anal Biochem. 373:88–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Menendez A and Scott JK: The nature of
target-unrelated peptides recovered in the screening of
phage-displayed random peptide libraries with antibodies. Anal
Biochem. 336:145–157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sasso E, D'Avino C, Passariello M, D'Alise
AM, Siciliano D, Esposito ML, Froechlich G, Cortese R, Scarselli E,
Zambrano N, et al: Massive parallel screening of phage libraries
for the generation of repertoires of human immunomodulatory
monoclonal antibodies. MAbs. 11:1–13. 2018. View Article : Google Scholar
|
|
57
|
Harper J, Mao S, Strout P and Kamal A:
Selecting an optimal antibody for antibody-drug conjugate therapy:
Internalization and intracellular localization. Methods Mol Biol.
1045:41–49, 2013.0. View Article : Google Scholar : PubMed/NCBI
|
